Molnupiravir pill, new hope to fight COVID-19 From the results of the second phase of the trial, it was found to be quite good. Foreign news agencies reported that "Merck" (Merck), a giant drug manufacturer from Germany, in collaboration with Ridgeback. Ridgeback Biotherapeutics has developed a new anti-corona virus (SARS-CoV-2) tablet called Molnupiravir. (molnupiravir), last week preliminarily announced that the drug was successful in a Phase II trial of 202 COVID-19 patients who had mild symptoms and had not yet been admitted. HospitalizationMore pictures, click jackpotสล็อต


In the trial, both patients received a placebo and a real drug. It was found that the patients who received the real drug for 5 consecutive days had significantly decreased viral load without any side effects or adverse reactions. And have not found any problems with the safety of drug use

Wendy Painter, Ridgback's chief medical officer, said the initial data was heartening, as no cure for COVID-19 has yet been discovered.
The company will continue to conduct trials and assess results in both outpatient and nursing homes to develop a plan for the development of anti-COVID-19 drugs. Safe and effective It is expected that the results of the next trial will be disclosed within this quarter. While the FDA still wants more information

Molnupiravir, or EIDD-2801, is an analog nucleoside treatment that is broadly active against RNA viruses. (RNA viruses as the genetic material), including influenza, SARS and MERS viruses.